Hematology
4 drugs are in development for Sickle Cell Disease.
- Companies
- 4
- Clinical trials
- 77
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Sickle Cell Disease pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| endari | Emmaus Life Sciences, Inc. (EMMA) |
Phase 2(1)
| Drug | Company |
|---|---|
| Tebapivat | AGIOS PHARMACEUTICALS, INC. (AGIO) |
Phase 1(1)
| Drug | Company |
|---|---|
| pociredir | Fulcrum Therapeutics, Inc. (FULC) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| BEAM-101 | Beam Therapeutics Inc. (BEAM) |
About this indication
Sickle Cell Disease context
Hematology·MeSH: Anemia, Sickle Cell (D000755)
Also known as: Anemias, Sickle Cell, Cell Diseases, Sickle, Cell Disorder, Sickle, Cell Disorders, Sickle, Disease, Hemoglobin S, HbS Disease, Hemoglobin S Diseases, Sickle Cell Anemia, Sickling Disorder Due to Hemoglobin S
Prevalence
10.0 / 100K
Incidence
3.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Sickle Cell Disease?
BioSniper tracks 4 drugs in development for Sickle Cell Disease across 4 companies.
How many clinical trials target Sickle Cell Disease?
There are 77 clinical trials targeting Sickle Cell Disease tracked by BioSniper.
What is the prevalence of Sickle Cell Disease?
The estimated prevalence of Sickle Cell Disease is approximately 10.0 per 100,000 population.